Folate mimetics and folate-receptor binding conjugates thereof
This present disclosure relates to folate mimetics and their use in therapeutic and diagnostic applications. More particularly, the disclosure relates to using des-glutamyl folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such analogs for targeted delivery of diagnostic or therapeutic agents to folate-receptor bearing cell populations.
1. A compound having the formula
wherein
X and Y are each independently selected from the group consisting of halo, R 2 , OR 2 , SR 3 , and NR 4 R 5 ;
U and W are each —N═;
V is —(R 6′ )C═ or —(R 6′ )C(R 7′ )—;
Q is selected from the group consisting of C and CH;
T is selected from the group consisting of S, O, N and —C═C— such that the ring structure of which T is a member is aromatic;
A 1 and A 2 are each independently selected from the group consisting of —C(S)—, —C(Z)O—, —OC(Z)—, —N(R 4″ )—, —C(Z)—N(R 4″ )—, —N(R 4″ )—C(Z), —O—C(Z)—N(R 4″ )—, —N(R 4″ )—C(Z)—O—, —N(R 4″ )—C(Z)—N(R 5″ )—, —O—, —S—, —S(O)—, —S(O) 2— , —N(R 4″ )S(O) 2— , —C(R 6″ )(R 7″ )—, —N(C≡CH)—, —N(CH 2 —C≡CH)—, C 1 -C 12 alkyl and C 1 -C 12 alkoxy; where Z is oxygen or sulfur provided that A 2 does not represent —C(O)NH—;
R 1 is selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy;
R 2 , R 3 , R 4 , R 4′ , R 4″ , R 5 , R 5″ , R 6″ and R 7″ are each independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 1 -C 12 alkanoyl, C 1 -C 12 alkenyl, C 1 -C 12 alkynyl, (C 1 -C 12 alkoxy)carbonyl, and (C 1 -C 12 alkylamino)carbonyl;
R 6 and R 7 are each independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; or R 6 and R 7 are taken together to form O═;
R 6′ and R 7′ are each independently selected from the group consisting of hydrogen, halo, C 1 -C 12 alkyl, and C 1 -C 12 alkoxy; or —R 6′ and R 7′ are taken together to form O═;
L is a divalent linker;
n, p, r and s are each independently either 0 or 1 provided when n=1, then r=1; and
B is a leaving group;
provided that the linker L does not include a naturally occurring amino acid covalently linked to A 2 at it's a-amino group through an amide bond.
2. The compound of claim 1 wherein
X and Y are each independently selected from the group consisting of hydrogen, halo, CH 3 , OH, SH and NH 2 ;
Q represents C;
A 1 is selected from the group consisting of —C(S)—, —NH—, —N(CH 3 )—, —O—, —S—, —S(O)—, —S(O) 2— , —CH 2— , —CH(CH 3 )—, —C(CH 3 ) 2— , —N(CH 2 —C≡CH)—, and —N(C≡CH)—;
R 1 is selected from the group consisting of hydrogen, halo and methyl;
R 6 and R 7 are each independently selected from the group consisting of hydrogen, halo, CH 3 , OH, SH and NH 2 ; or R 6 and R 7 are taken together to form O═;
A 2 is selected from the group consisting of —C(S)—, —C(Z)O—, —OC(Z)—, —N(R 4″ )—, —C(Z)—N(R 4″ )—, —N(R 4″ )—C(Z)—, —O—C(Z)—N(R 4″ )—, —N(R 4″ )—C(Z)—O—, —N(R 4″ )—C(Z)N(R 5″ )—, —O—, —S—, —S(O)—, —S(O) 2— , —N(R 4″ )S(O) 2— , —C(R 6″ )(R 7″ )—, C 1 -C 6 alky; C 1 -C 6 alkoxy; provided that A 2 does not represent —C(O)NH—; and
p and r are each 1.
3. The compound of claim 2 wherein T is —C═C—.
4. The compound of claim 2 wherein X is OH.
5. The compound of claim 1 wherein X is OH; Y is NH 2 ;
V is —(R 6′ )C═; Q is C; T is —C═C—; A 1 is —NH; R 1 is hydrogen;
A 2 is —C(O)O— and is para to A 1 ; R 6 and R 7 are each H; and p, r, and s are each 1.
6. A compound that is isosteric with the compound of claim 5 .
7. The compound of claim 1 wherein L comprises a linear or branched chain comprising a plurality of linking groups L 1 , L 2 , . . . , L m , wherein m is an integer from 0 to about 50.
8. The compound of claim 7 wherein m is an integer from about 1 to about 20.